EA202190603A1 - Полипептиды анти-her2 и способы их применения - Google Patents

Полипептиды анти-her2 и способы их применения

Info

Publication number
EA202190603A1
EA202190603A1 EA202190603A EA202190603A EA202190603A1 EA 202190603 A1 EA202190603 A1 EA 202190603A1 EA 202190603 A EA202190603 A EA 202190603A EA 202190603 A EA202190603 A EA 202190603A EA 202190603 A1 EA202190603 A1 EA 202190603A1
Authority
EA
Eurasian Patent Office
Prior art keywords
her2
antibody
methods
bbb
application
Prior art date
Application number
EA202190603A
Other languages
English (en)
Inventor
Марк С. Деннис
Ванда Кван
Джозеф В. Льюкок
Джонатан Соколоски
Джой Ю Дзукеро
Original Assignee
Денали Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Денали Терапьютикс Инк. filed Critical Денали Терапьютикс Инк.
Publication of EA202190603A1 publication Critical patent/EA202190603A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Данное изобретение относится к конструкциям анти-HER2, таким как слитый белок димер полипептида Fc-вариабельная область антитела, которые проникают через ГЭБ и связываются с HER2 в паренхиме головного мозга. В некоторых вариантах осуществления конструкции анти-HER2 (например, слитые белки димер полипептида Fc-вариабельная область антитела) сохраняют эффекторную функцию при связывании с HER2, но не приводят к существенному истощению популяции ретикулоцитов in vivo. Данное изобретение также относится к способам трансцитоза вариабельной области антитела анти-HER2 через ГЭБ и лечения HER2-положительных онкологических заболеваний и их метастатических поражений.
EA202190603A 2018-08-22 2019-08-22 Полипептиды анти-her2 и способы их применения EA202190603A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721505P 2018-08-22 2018-08-22
PCT/US2019/047728 WO2020041604A1 (en) 2018-08-22 2019-08-22 Anti-her2 polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
EA202190603A1 true EA202190603A1 (ru) 2021-07-14

Family

ID=67989062

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190603A EA202190603A1 (ru) 2018-08-22 2019-08-22 Полипептиды анти-her2 и способы их применения

Country Status (15)

Country Link
US (1) US20220002436A1 (ru)
EP (1) EP3840781A1 (ru)
JP (1) JP2021534220A (ru)
KR (1) KR20210074279A (ru)
CN (1) CN113286610A (ru)
AR (1) AR115998A1 (ru)
AU (1) AU2019326545A1 (ru)
BR (1) BR112021002953A2 (ru)
CA (1) CA3141815A1 (ru)
EA (1) EA202190603A1 (ru)
IL (1) IL280922A (ru)
MX (1) MX2021001976A (ru)
SG (1) SG11202101436SA (ru)
TW (1) TW202017947A (ru)
WO (1) WO2020041604A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA127985C2 (uk) 2017-02-17 2024-03-06 Деналі Терап'Ютікс Інк. Сконструйований поліпептид, який зв'язує трансфериновий рецептор
MX2020002918A (es) 2017-10-02 2020-07-22 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas.
KR20220130678A (ko) 2019-12-23 2022-09-27 데날리 테라퓨틱스 인크. 프로그라눌린 변이체들
CA3166385A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
KR20230086703A (ko) 2020-10-14 2023-06-15 데날리 테라퓨틱스 인크. 설포글루코사민 설포하이드롤라제 효소를 포함하는 융합 단백질 및 이의 방법
CN118119402A (zh) * 2021-08-25 2024-05-31 戴纳立制药公司 工程化抗her2双特异性蛋白
WO2023128702A1 (ko) * 2021-12-31 2023-07-06 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
KR20240067001A (ko) * 2022-10-28 2024-05-16 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3315514A1 (en) * 2012-08-29 2018-05-02 F. Hoffmann-La Roche AG Blood brain barrier shuttle
JP2016501881A (ja) * 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質
US20160002343A1 (en) * 2014-06-11 2016-01-07 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
WO2016207091A1 (en) * 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
CA3053379A1 (en) * 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
UA127985C2 (uk) * 2017-02-17 2024-03-06 Деналі Терап'Ютікс Інк. Сконструйований поліпептид, який зв'язує трансфериновий рецептор

Also Published As

Publication number Publication date
JP2021534220A (ja) 2021-12-09
CN113286610A (zh) 2021-08-20
IL280922A (en) 2021-04-29
MX2021001976A (es) 2021-06-08
SG11202101436SA (en) 2021-03-30
TW202017947A (zh) 2020-05-16
EP3840781A1 (en) 2021-06-30
CA3141815A1 (en) 2020-02-27
US20220002436A1 (en) 2022-01-06
AU2019326545A1 (en) 2021-03-11
WO2020041604A1 (en) 2020-02-27
AR115998A1 (es) 2021-03-25
KR20210074279A (ko) 2021-06-21
BR112021002953A2 (pt) 2021-05-11

Similar Documents

Publication Publication Date Title
EA202190603A1 (ru) Полипептиды анти-her2 и способы их применения
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
MX2023007520A (es) Aglutinantes de albumina de suero mejorados.
MX2023005374A (es) Aglutinantes de albumina serica mejorados.
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
EA201990781A9 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
MX2019008536A (es) Aglutinantes de albumina serica mejorados.
ATE509032T1 (de) Chimerizierte gm-csf antikörper
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
KR20140112515A (ko) 경쇄-가교된 이중특이성 항체
EA201591700A1 (ru) Гибридные белки апелина и их применение
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
MX2022001049A (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
EA201992467A1 (ru) ГЕТЕРОДИМЕРИЗУЮЩИЕСЯ ДОМЕНЫ Ig
CR20210628A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos
MX2021010281A (es) Proteinas de enlace a antigenos que se enlazan al bcma.
MX2023001256A (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos.
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
EA202190235A1 (ru) Антитела к cd33 и способы их применения
BR112022010824A2 (pt) Anticorpo bifuncional contra pd-l1 e tgf¿
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
MX2021014336A (es) Caracterizacion de variantes de carga especificas del dominio de anticuerpos.
EA202092593A1 (ru) Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение